Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Orphanet Journal of Rare Diseases
Published in: Orphanet Journal of Rare Diseases 1/2019

Open Access 01-12-2019 | Hypophosphatemic Rickets | Review

FGF23 and its role in X-linked hypophosphatemia-related morbidity

Authors: Signe Sparre Beck-Nielsen, Zulf Mughal, Dieter Haffner, Ola Nilsson, Elena Levtchenko, Gema Ariceta, Carmen de Lucas Collantes, Dirk Schnabel, Ravi Jandhyala, Outi Mäkitie

Published in: Orphanet Journal of Rare Diseases | Issue 1/2019

Login to get access

Abstract

Background

X-linked hypophosphatemia (XLH) is an inherited disease of phosphate metabolism in which inactivating mutations of the Phosphate Regulating Endopeptidase Homolog, X-Linked (PHEX) gene lead to local and systemic effects including impaired growth, rickets, osteomalacia, bone abnormalities, bone pain, spontaneous dental abscesses, hearing difficulties, enthesopathy, osteoarthritis, and muscular dysfunction. Patients with XLH present with elevated levels of fibroblast growth factor 23 (FGF23), which is thought to mediate many of the aforementioned manifestations of the disease. Elevated FGF23 has also been observed in many other diseases of hypophosphatemia, and a range of animal models have been developed to study these diseases, yet the role of FGF23 in the pathophysiology of XLH is incompletely understood.

Methods

The role of FGF23 in the pathophysiology of XLH is here reviewed by describing what is known about phenotypes associated with various PHEX mutations, animal models of XLH, and non-nutritional diseases of hypophosphatemia, and by presenting molecular pathways that have been proposed to contribute to manifestations of XLH.

Results

The pathophysiology of XLH is complex, involving a range of molecular pathways that variously contribute to different manifestations of the disease. Hypophosphatemia due to elevated FGF23 is the most obvious contributor, however localised fluctuations in tissue non-specific alkaline phosphatase (TNAP), pyrophosphate, calcitriol and direct effects of FGF23 have been observed to be associated with certain manifestations.

Conclusions

By describing what is known about these pathways, this review highlights key areas for future research that would contribute to the understanding and clinical treatment of non-nutritional diseases of hypophosphatemia, particularly XLH.
Literature
1.
Beck-Nielsen SS, Brock-Jacobsen B, Gram J, Brixen K, Jensen TK. Incidence and prevalence of nutritional and hereditary rickets in southern Denmark. Eur J Endocrinol. 2009;160:491–7.PubMedCrossRef
2.
Reid IR, Hardy DC, Murphy WA, Teitelbaum SL, Bergfeld MA, Whyte MP. X-Linked Hypophosphatemia: A Clinical, Biochemical, and Histopathologic Assessment of Morbidity in Adults. Medicine (Baltimore). 1989;68:336.CrossRef
3.
Carpenter TO, Imel EA, Holm IA, Jan de Beur SM, Insogna KL. A clinician’s guide to X-linked hypophosphatemia. J Bone Miner Res. 2011;26:1381–8.PubMedCrossRef
4.
Barros NM, Hoac B, Neves RL, Addison WN, Assis DM, Murshed M, et al. Proteolytic processing of osteopontin by PHEX and accumulation of osteopontin fragments in Hyp mouse bone, the murine model of X-linked hypophosphatemia. J Bone Min Res. 2013;28:688–99.CrossRef
5.
Liu S, Guo R, Simpson LG, Xiao Z-S, Burnham CE, Quarles LD. Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX. J Biol Chem. 2003;278:37419–26.PubMedCrossRef
6.
Benet-Pages A, Lorenz-Depiereux B, Zischka H, White KE, Econs MJ, Strom TM. FGF23 is processed by proprotein convertases but not by PHEX. Bone. 2004;35:455–62.PubMedCrossRef
7.
Murali SK, Andrukhova O, Clinkenbeard EL, White KE, Erben RG. Excessive Osteocytic Fgf23 Secretion Contributes to Pyrophosphate Accumulation and Mineralization Defect in Hyp Mice. PLoS Biol. 2016;14:e1002427.PubMedPubMedCentralCrossRef
8.
Imel EA, DiMeglio LA, Hui SL, Carpenter TO, Econs MJ. Treatment of X-linked hypophosphatemia with calcitriol and phosphate increases circulating fibroblast growth factor 23 concentrations. J Clin Endocrinol Metab. 2010;95:1846–50.PubMedPubMedCentralCrossRef
9.
Linglart A, Biosse-Duplan M, Briot K, Chaussain C, Esterle L, Guillaume-Czitrom S, et al. Therapeutic management of hypophosphatemic rickets from infancy to adulthood. Endocr Connect. 2014;3:R13–30.PubMedPubMedCentralCrossRef
10.
Makitie O, Doria A, Kooh SW, Cole WG, Daneman A, Sochett E. Early treatment improves growth and biochemical and radiographic outcome in X-linked hypophosphatemic rickets. J Clin Endocrinol Metab. 2003;88:3591–7.PubMedCrossRef
11.
Antoniucci DM, Yamashita T, Portale AA. Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men. J Clin Endocrinol Metab. 2006;91:3144–9.PubMedCrossRef
12.
Burnett SM, Gunawardene SC, Bringhurst FR, Juppner H, Lee H, Finkelstein JS. Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. J Bone Min Res. 2006;21:1187–96.CrossRef
13.
Alon US, Levy-Olomucki R, Moore WV, Stubbs J, Liu S, Quarles LD. Calcimimetics as an adjuvant treatment for familial hypophosphatemic rickets. Clin J Am Soc Nephrol. 2008;3:658–64.PubMedPubMedCentralCrossRef
14.
Raeder H, Shaw N, Netelenbos C, Bjerknes R. A case of X-linked hypophosphatemic rickets: complications and the therapeutic use of cinacalcet. Eur J Endocrinol. 2008;159(Suppl 1):S101–5.PubMedCrossRef
15.
Bai X, Miao D, Xiao S, Qiu D, St-Arnaud R, Petkovich M, et al. CYP24 inhibition as a therapeutic target in FGF23-mediated renal phosphate wasting disorders. J Clin Invest. 2016;126:667–80.PubMedPubMedCentralCrossRef
16.
Yamashita T, Yoshioka M, Itoh N. Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochem Biophys Res Commun. 2000;277:494–8.PubMedCrossRef
17.
Yoshiko Y, Wang H, Minamizaki T, Ijuin C, Yamamoto R, Suemune S, et al. Mineralized tissue cells are a principal source of FGF23. Bone. 2007;40:1565–73.PubMedCrossRef
18.
Jiang B, Cao Z, Lu Y, Janik C, Lauziere S, Xie Y, et al. DMP1 C-terminal mutant mice recapture the human ARHR tooth phenotype. J Bone Min Res. 2010;25:2155–64.CrossRef
19.
Tagliabracci VS, Engel JL, Wiley SE, Xiao J, Gonzalez DJ, Nidumanda Appaiah H, et al. Dynamic regulation of FGF23 by Fam20C phosphorylation, GalNAc-T3 glycosylation, and furin proteolysis. Proc Natl Acad Sci U A. 2014;111:5520–5.CrossRef
20.
Shimada T, Muto T, Urakawa I, Yoneya T, Yamazaki Y, Okawa K, et al. Mutant FGF-23 Responsible for Autosomal Dominant Hypophosphatemic Rickets Is Resistant to Proteolytic Cleavage and Causes Hypophosphatemia in Vivo. Endocrinology. 2002;143:3179–82.PubMedCrossRef
21.
Saito H, Maeda A, Ohtomo S, Hirata M, Kusano K, Kato S, et al. Circulating FGF-23 is regulated by 1alpha,25-dihydroxyvitamin D3 and phosphorus in vivo. J Biol Chem. 2005;280:2543–9.PubMedCrossRef
22.
Clinkenbeard EL, Cass TA, Ni P, Hum JM, Bellido T, Allen MR, et al. Conditional Deletion of Murine Fgf23: Interruption of the Normal Skeletal Responses to Phosphate Challenge and Rescue of Genetic Hypophosphatemia. J Bone Min Res. 2016;31:1247–57.CrossRef
23.
Scanni R, vonRotz M, Jehle S, Hulter HN, Krapf R. The human response to acute enteral and parenteral phosphate loads. J Am Soc Nephrol. 2014;25:2730–9.PubMedPubMedCentralCrossRef
24.
Hori M, Kinoshita Y, Taguchi M, Fukumoto S. Phosphate enhances Fgf23 expression through reactive oxygen species in UMR-106 cells. J Bone Min Metab. 2016;34:132–9.CrossRef
25.
Wang X, Wang S, Li C, Gao T, Liu Y, Rangiani A, et al. Inactivation of a Novel FGF23 Regulator, FAM20C, Leads to Hypophosphatemic Rickets in Mice. PLOS Genet. 2012;8:e1002708.PubMedPubMedCentralCrossRef
26.
Lorenz-Depiereux B, Schnabel D, Tiosano D, Hausler G, Strom TM. Loss-of-function ENPP1 mutations cause both generalized arterial calcification of infancy and autosomal-recessive hypophosphatemic rickets. Am J Hum Genet. 2010;86:267–72.PubMedPubMedCentralCrossRef
27.
Samadfam R, Richard C, Nguyen-Yamamoto L, Bolivar I, Goltzman D. Bone formation regulates circulating concentrations of fibroblast growth factor 23. Endocrinology. 2009;150:4835–45.PubMedCrossRef
28.
Liu S, Rowe PS, Vierthaler L, Zhou J, Quarles LD. Phosphorylated acidic serine-aspartate-rich MEPE-associated motif peptide from matrix extracellular phosphoglycoprotein inhibits phosphate regulating gene with homologies to endopeptidases on the X-chromosome enzyme activity. J Endocrinol. 2007;192:261–7.PubMedPubMedCentralCrossRef
29.
Fajol A, Honisch S, Zhang B, Schmidt S, Alkahtani S, Alarifi S, et al. Fibroblast growth factor (Fgf) 23 gene transcription depends on actin cytoskeleton reorganization. FEBS Lett. 2016;590:705–15.PubMedCrossRef
30.
Zhang B, Umbach AT, Chen H, Yan J, Fakhri H, Fajol A, et al. Up-regulation of FGF23 release by aldosterone. Biochem Biophys Res Commun. 2016;470:384–90.PubMedCrossRef
31.
Zhang B, Yan J, Umbach AT, Fakhri H, Fajol A, Schmidt S, et al. NFkappaB-sensitive Orai1 expression in the regulation of FGF23 release. J Mol Med Berl. 2016;94:557–66.PubMedCrossRef
32.
Leifheit-Nestler M, Kucka J, Yoshizawa E, Behets G, D’Haese P, Bergen C, et al. Comparison of calcimimetic R568 and calcitriol in mineral homeostasis in the Hyp mouse, a murine homolog of X-linked hypophosphatemia. Bone. 2017;103:224–32.PubMedCrossRef
33.
Nguyen-Yamamoto L, Karaplis AC, St-Arnaud R, Goltzman D. Fibroblast Growth Factor 23 Regulation by Systemic and Local Osteoblast-Synthesized 1,25-Dihydroxyvitamin D. J Am Soc Nephrol. 2017;28:586–97.PubMedCrossRef
34.
Yamamoto H, Ramos-Molina B, Lick AN, Prideaux M, Albornoz V, Bonewald L, et al. Posttranslational processing of FGF23 in osteocytes during the osteoblast to osteocyte transition. Bone. 2016;84:120–30.PubMedCrossRef
35.
Frishberg Y, Ito N, Rinat C, Yamazaki Y, Feinstein S, Urakawa I, et al. Hyperostosis-hyperphosphatemia syndrome: a congenital disorder of O-glycosylation associated with augmented processing of fibroblast growth factor 23. J Bone Min Res. 2007;22:235–42.CrossRef
36.
Kato K, Jeanneau C, Tarp MA, Benet-Pages A, Lorenz-Depiereux B, Bennett EP, et al. Polypeptide GalNAc-transferase T3 and familial tumoral calcinosis. Secretion of fibroblast growth factor 23 requires O-glycosylation. J Biol Chem. 2006;281:18370–7.PubMedCrossRef
37.
Ichikawa S, Imel EA, Sorenson AH, Severe R, Knudson P, Harris GJ, et al. Tumoral Calcinosis Presenting with Eyelid Calcifications due to Novel Missense Mutations in the Glycosyl Transferase Domain of the GALNT3 Gene. J Clin Endocrinol Metab. 2006;91:4472–5.PubMedCrossRef
38.
Yuan B, Feng JQ, Bowman S, Liu Y, Blank RD, Lindberg I, et al. Hexa-D-arginine treatment increases 7B2*PC2 activity in hyp-mouse osteoblasts and rescues the HYP phenotype. J Bone Min Res. 2013;28:56–72.CrossRef
39.
David V, Martin A, Isakova T, Spaulding C, Qi L, Ramirez V, et al. Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production. Kidney Int. 2016;89:135–46.PubMedPubMedCentralCrossRef
40.
Rowe PS. Regulation of bone-renal mineral and energy metabolism: the PHEX, FGF23, DMP1, MEPE ASARM pathway. Crit Rev Eukaryot Gene Expr. 2012;22:61–86.PubMedPubMedCentralCrossRef
41.
Kawai M. The FGF23/Klotho axis in the regulation of mineral and metabolic homeostasis. Horm Mol Biol Clin Investig. 2016;28:55–67.PubMed
42.
43.
Kurosu H, Ogawa Y, Miyoshi M, Yamamoto M, Nandi A, Rosenblatt KP, et al. Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem. 2006;281:6120–3.PubMedCrossRef
44.
Rossaint J, Oehmichen J, Van Aken H, Reuter S, Pavenstadt HJ, Meersch M, et al. FGF23 signaling impairs neutrophil recruitment and host defense during CKD. J Clin Invest. 2016;126:962–74.PubMedPubMedCentralCrossRef
45.
46.
Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature. 1997;390:45–51.PubMedCrossRef
47.
Bai X, Dinghong Q, Miao D, Goltzman D, Karaplis AC. Klotho ablation converts the biochemical and skeletal alterations in FGF23 (R176Q) transgenic mice to a Klotho-deficient phenotype. Am J Physiol Endocrinol Metab. 2009;296:E79–88.PubMedCrossRef
48.
Olauson H, Mencke R, Hillebrands JL, Larsson TE. Tissue expression and source of circulating alphaKlotho. Bone. 2017;100:19–35.PubMedCrossRef
49.
Murali SK, Roschger P, Zeitz U, Klaushofer K, Andrukhova O, Erben RG. FGF23 Regulates Bone Mineralization in a 1,25(OH)2 D3 and Klotho-Independent Manner. J Bone Min Res. 2016;31:129–42.CrossRef
50.
Goetz R, Nakada Y, Hu MC, Kurosu H, Wang L, Nakatani T, et al. Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formation. Proc Natl Acad Sci U A. 2010;107:407–12.CrossRef
51.
ADHR Consortium. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet. 2000;26:345–8.CrossRef
52.
Feng JQ, Ward LM, Liu S, Lu Y, Xie Y, Yuan B, et al. Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet. 2006;38:1310–5.PubMedPubMedCentralCrossRef
53.
Brownstein CA, Adler F, Nelson-Williams C, Iijima J, Li P, Imura A, et al. A translocation causing increased alpha-klotho level results in hypophosphatemic rickets and hyperparathyroidism. Proc Natl Acad Sci U A. 2008;105:3455–60.CrossRef
54.
Lorenz-Depiereux B, Benet-Pages A, Eckstein G, Tenenbaum-Rakover Y, Wagenstaller J, Tiosano D, et al. Hereditary hypophosphatemic rickets with hypercalciuria is caused by mutations in the sodium-phosphate cotransporter gene SLC34A3. Am J Hum Genet. 2006;78:193–201.PubMedCrossRef
55.
Khosravi A, Cutler CM, Kelly MH, Chang R, Royal RE, Sherry RM, et al. Determination of the elimination half-life of fibroblast growth factor-23. J Clin Endocrinol Metab. 2007;92:2374–7.PubMedCrossRef
56.
57.
Beck-Nielsen SS, Brusgaard K, Rasmussen LM, Brixen K, Brock-Jacobsen B, Poulsen MR, et al. Phenotype presentation of hypophosphatemic rickets in adults. Calcif Tissue Int. 2010;87:108–19.PubMedCrossRef
58.
Gaucher C, Walrant-Debray O, Nguyen T-M, Esterle L, Garabédian M, Jehan F. PHEX analysis in 118 pedigrees reveals new genetic clues in hypophosphatemic rickets. Hum Genet. 2009;125:401–11.PubMedCrossRef
59.
Popowska E, Pronicka E, Sulek A, Jurkiewicz D, Rowe P, Rowinska E, et al. X-linked hypophosphatemia in Polish patients. 1. Mutations in the PHEX gene. J Appl Genet. 2000;41:293–302.PubMed
60.
Sabbagh Y, Boileau G, DesGroseillers L, Tenenhouse HS. Disease-causing missense mutations in the PHEX gene interfere with membrane targeting of the recombinant protein. Hum Mol Genet. 2001;10:1539–46.PubMedCrossRef
61.
Beck-Nielsen SS, Brixen K, Gram J, Brusgaard K. Mutational analysis of PHEX, FGF23, DMP1, SLC34A3 and CLCN5 in patients with hypophosphatemic rickets. J Hum Genet. 2012;57:453–8.PubMedCrossRef
62.
Han F, Yu H, Li P, Zhang J, Tian C, Li H, et al. Mutation in Phex gene predisposes BALB/c-Phex(Hyp-Duk)/Y mice to otitis media. PLoS One. 2012;7:e43010.PubMedPubMedCentralCrossRef
63.
Yang X, Yan W, Tian Y, Ma P, Opperman LA, Wang X. Family with sequence similarity member 20C is the primary but not the only kinase for the small-integrin-binding ligand N-linked glycoproteins in bone. Faseb J. 2016;30:121–8.PubMedCrossRef
64.
Song H-R, Park J-W, Cho D-Y, Yang JH, Yoon H-R, Jung S-C. PHEX Gene Mutations and Genotype-Phenotype Analysis of Korean Patients with Hypophosphatemic Rickets. J Korean Med Sci. 2007;22:981–6.PubMedPubMedCentralCrossRef
65.
Morey M, Castro-Feijoo L, Barreiro J, Cabanas P, Pombo M, Gil M, et al. Genetic diagnosis of X-linked dominant Hypophosphatemic Rickets in a cohort study: tubular reabsorption of phosphate and 1,25(OH)2D serum levels are associated with PHEX mutation type. BMC Med Genet. 2011;12:116.PubMedPubMedCentralCrossRef
66.
Nakamura Y, Takagi M, Takeda R, Miyai K, Hasegawa Y. Hypertension is a characteristic complication of X-linked hypophosphatemia. Endocr J. 2017;64:283–9.PubMedCrossRef
67.
Chesher D, Oddy M, Darbar U, Sayal P, Casey A, Ryan A, et al. Outcome of adult patients with X-linked hypophosphatemia caused by PHEX gene mutations. J Inherit Metab Dis. 2018;41:865–76.PubMedPubMedCentralCrossRef
68.
69.
Eicher EM, Southard JL, Scriver CR, Glorieux FH. Hypophosphatemia: mouse model for human familial hypophosphatemic (vitamin D-resistant) rickets. Proc Natl Acad Sci U A. 1976;73:4667–71.CrossRef
70.
Lyon MF, Scriver CR, Baker LR, Tenenhouse HS, Kronick J, Mandla S. The Gy mutation: another cause of X-linked hypophosphatemia in mouse. Proc Natl Acad Sci U A. 1986;83:4899–903.CrossRef
71.
Sabbagh Y, Gauthier C, Tenenhouse HS. The X chromosome deletion in HYP mice extends into the intergenic region but does not include the SAT gene downstream from Phex. Cytogenet Genome Res. 2002;99:344–9.PubMedCrossRef
72.
Du L, Desbarats M, Cornibert S, Malo D, Ecarot B. Fine genetic mapping of the Hyp mutation on mouse chromosome X. Genomics. 1996;32:177–83.PubMedCrossRef
73.
Lorenz B, Francis F, Gempel K, Boddrich A, Josten M, Schmahl W, et al. Spermine deficiency in Gy mice caused by deletion of the spermine synthase gene. Hum Mol Genet. 1998;7:541–7.PubMedCrossRef
74.
Erben RG, Mayer D, Weber K, Jonsson K, Juppner H, Lanske B. Overexpression of human PHEX under the human beta-actin promoter does not fully rescue the Hyp mouse phenotype. J Bone Min Res. 2005;20:1149–60.CrossRef
75.
Carpinelli MR, Wicks IP, Sims NA, O’Donnell K, Hanzinikolas K, Burt R, et al. An ethyl-nitrosourea-induced point mutation in phex causes exon skipping, x-linked hypophosphatemia, and rickets. Am J Pathol. 2002;161:1925–33.PubMedPubMedCentralCrossRef
76.
Owen C, Chen F, Flenniken AM, Osborne LR, Ichikawa S, Adamson SL, et al. A novel Phex mutation in a new mouse model of hypophosphatemic rickets. J Cell Biochem. 2012;113:2432–41.PubMedCrossRef
77.
Lorenz-Depiereux B, Guido VE, Johnson KR, Zheng QY, Gagnon LH, Bauschatz JD, et al. New intragenic deletions in the Phex gene clarify X-linked hypophosphatemia-related abnormalities in mice. Mamm Genome. 2004;15:151–61.PubMedPubMedCentralCrossRef
78.
Zivicnjak M, Schnabel D, Staude H, Even G, Marx M, Beetz R, et al. Three-year growth hormone treatment in short children with X-linked hypophosphatemic rickets: effects on linear growth and body disproportion. J Clin Endocrinol Metab. 2011;96:E2097–105.PubMedCrossRef
79.
Gerber HP, Vu TH, Ryan AM, Kowalski J, Werb Z, Ferrara N. VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat Med. 1999;5:623–8.PubMedCrossRef
80.
Tiosano D, Hochberg Z. Hypophosphatemia: the common denominator of all rickets. J Bone Min Metab. 2009;27:392–401.CrossRef
81.
82.
Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U A. 2001;98:6500–5.CrossRef
83.
Sitara D, Razzaque MS, Hesse M, Yoganathan S, Taguchi T, Erben RG, et al. Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. Matrix Biol. 2004;23:421–32.PubMedPubMedCentralCrossRef
84.
Wang H, Yoshiko Y, Yamamoto R, Minamizaki T, Kozai K, Tanne K, et al. Overexpression of fibroblast growth factor 23 suppresses osteoblast differentiation and matrix mineralization in vitro. J Bone Min Res. 2008;23:939–48.CrossRef
85.
Sitara D, Kim S, Razzaque MS, Bergwitz C, Taguchi T, Schuler C, et al. Genetic evidence of serum phosphate-independent functions of FGF-23 on bone. PLoS Genet. 2008;4:e1000154.PubMedPubMedCentralCrossRef
86.
Saito H, Kusano K, Kinosaki M, Ito H, Hirata M, Segawa H, et al. Human fibroblast growth factor-23 mutants suppress Na+-dependent phosphate co-transport activity and 1alpha,25-dihydroxyvitamin D3 production. J Biol Chem. 2003;278:2206–11.PubMedCrossRef
87.
Segawa H, Kawakami E, Kaneko I, Kuwahata M, Ito M, Kusano K, et al. Effect of hydrolysis-resistant FGF23-R179Q on dietary phosphate regulation of the renal type-II Na/Pi transporter. Pflugers Arch. 2003;446:585–92.PubMedCrossRef
88.
Bai X, Miao D, Li J, Goltzman D, Karaplis AC. Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders. Endocrinology. 2004;145:5269–79.PubMedCrossRef
89.
Sabbagh Y, Carpenter TO, Demay MB. Hypophosphatemia leads to rickets by impairing caspase-mediated apoptosis of hypertrophic chondrocytes. Proc Natl Acad Sci U A. 2005;102:9637–42.CrossRef
90.
Larsson T, Marsell R, Schipani E, Ohlsson C, Ljunggren O, Tenenhouse HS, et al. Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. Endocrinology. 2004;145:3087–94.PubMedCrossRef
91.
Andrukhova O, Zeitz U, Goetz R, Mohammadi M, Lanske B, Erben RG. FGF23 acts directly on renal proximal tubules to induce phosphaturia through activation of the ERK1/2-SGK1 signaling pathway. Bone. 2012;51:621–8.PubMedPubMedCentralCrossRef
92.
Segawa H, Onitsuka A, Furutani J, Kaneko I, Aranami F, Matsumoto N, et al. Npt2a and Npt2c in mice play distinct and synergistic roles in inorganic phosphate metabolism and skeletal development. Am J Physiol Ren Physiol. 2009;297:F671–8.CrossRef
93.
Myakala K, Motta S, Murer H, Wagner CA, Koesters R, Biber J, et al. Renal-specific and inducible depletion of NaPi-IIc/Slc34a3, the cotransporter mutated in HHRH, does not affect phosphate or calcium homeostasis in mice. Am J Physiol Ren Physiol. 2014;306:F833–43.CrossRef
94.
Shimada T, Yamazaki Y, Takahashi M, Hasegawa H, Urakawa I, Oshima T, et al. Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism. Am J Physiol Ren Physiol. 2005;289:F1088–95.CrossRef
95.
Tenenhouse HS, Beck L. Renal Na(+)-phosphate cotransporter gene expression in X-linked Hyp and Gy mice. Kidney Int. 1996;49:1027–32.PubMedCrossRef
96.
Olauson H, Lindberg K, Amin R, Sato T, Jia T, Goetz R, et al. Parathyroid-specific deletion of Klotho unravels a novel calcineurin-dependent FGF23 signaling pathway that regulates PTH secretion. PLoS Genet. 2013;9:e1003975.PubMedPubMedCentralCrossRef
97.
Rizzoli R, Fleisch H, Bonjour JP. Role of 1,25-dihydroxyvitamin D3 on intestinal phosphate absorption in rats with a normal vitamin D supply. J Clin Invest. 1977;60:639–47.PubMedPubMedCentralCrossRef
98.
Syal A, Schiavi S, Chakravarty S, Dwarakanath V, Quigley R, Baum M. Fibroblast growth factor-23 increases mouse PGE2 production in vivo and in vitro. Am J Physiol Ren Physiol. 2006;290:F450–5.CrossRef
99.
Baum M, Loleh S, Saini N, Seikaly M, Dwarakanath V, Quigley R. Correction of proximal tubule phosphate transport defect in Hyp mice in vivo and in vitro with indomethacin. Proc Natl Acad Sci U A. 2003;100:11098–103.CrossRef
100.
Seikaly MG, Waber PG, Baum M. Urinary prostaglandins and the effect of indomethacin on phosphate excretion in children with hypophosphatemic rickets. Pediatr Res. 2008;64:210–2.PubMedPubMedCentralCrossRef
101.
Shiang R, Thompson LM, Zhu YZ, Church DM, Fielder TJ, Bocian M, et al. Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia. Cell. 1994;78:335–42.PubMedCrossRef
102.
Xiao ZS, Crenshaw M, Guo R, Nesbitt T, Drezner MK, Quarles LD. Intrinsic mineralization defect in Hyp mouse osteoblasts. Am J Physiol. 1998;275(4 Pt 1):E700–8.PubMed
103.
van der Meijden K, van Essen HW, Bloemers FW, Schulten EA, Lips P, Bravenboer N. Regulation of CYP27B1 mRNA Expression in Primary Human Osteoblasts. Calcif Tissue Int. 2016;99:164–73.PubMedPubMedCentralCrossRef
104.
Underwood JL, DeLuca HF. Vitamin D is not directly necessary for bone growth and mineralization. Am J Physiol. 1984;246(6 Pt 1):E493–8.PubMed
105.
Chang PL, Ridall AL, Prince CW. Calcitriol regulation of osteopontin expression in mouse epidermal cells. Endocrinology. 1994;135:863–9.PubMedCrossRef
106.
Addison WN, Azari F, Sorensen ES, Kaartinen MT, McKee MD. Pyrophosphate inhibits mineralization of osteoblast cultures by binding to mineral, up-regulating osteopontin, and inhibiting alkaline phosphatase activity. J Biol Chem. 2007;282:15872–83.PubMedCrossRef
107.
Lieben L, Masuyama R, Torrekens S, Van Looveren R, Schrooten J, Baatsen P, et al. Normocalcemia is maintained in mice under conditions of calcium malabsorption by vitamin D-induced inhibition of bone mineralization. J Clin Invest. 2012;122:1803–15.PubMedPubMedCentralCrossRef
108.
Addison WN, Masica DL, Gray JJ, McKee MD. Phosphorylation-dependent inhibition of mineralization by osteopontin ASARM peptides is regulated by PHEX cleavage. J Bone Min Res. 2010;25:695–705.CrossRef
109.
Martin A, David V, Laurence JS, Schwarz PM, Lafer EM, Hedge A-M, et al. Degradation of MEPE, DMP1, and Release of SIBLING ASARM-Peptides (Minhibins): ASARM-Peptide(s) Are Directly Responsible for Defective Mineralization in HYP. Endocrinology. 2008;149:1757–72.PubMedCrossRef
110.
Staines KA, MacRae VE, Farquharson C. The importance of the SIBLING family of proteins on skeletal mineralisation and bone remodelling. J Endocrinol. 2012;214:241–55.PubMedCrossRef
111.
Neves RL, Chiarantin GM, Nascimento FD, Pesquero JB, Nader HB, Tersariol IL, et al. Expression and inactivation of osteopontin-degrading PHEX enzyme in squamous cell carcinoma. Int J Biochem Cell Biol. 2016;77(Pt A):155–64.PubMedCrossRef
112.
Salmon B, Bardet C, Khaddam M, Naji J, Coyac BR, Baroukh B, et al. MEPE-derived ASARM peptide inhibits odontogenic differentiation of dental pulp stem cells and impairs mineralization in tooth models of X-linked hypophosphatemia. PLoS One. 2013;8:e56749.PubMedPubMedCentralCrossRef
113.
Caballero D, Li Y, Ponsetto J, Zhu C, Bergwitz C. Impaired urinary osteopontin excretion in Npt2a-/- mice. Am J Physiol Ren Physiol. 2017;312:F77–f83.CrossRef
114.
Yuan Q, Jiang Y, Zhao X, Sato T, Densmore M, Schüler C, et al. Increased osteopontin contributes to inhibition of bone mineralization in FGF23-deficient mice. J Bone Miner Res Off J Am Soc Bone Miner Res. 2014;29:693–704.CrossRef
115.
Narisawa S, Frohlander N, Millan JL. Inactivation of two mouse alkaline phosphatase genes and establishment of a model of infantile hypophosphatasia. Dev Dyn. 1997;208:432–46.PubMedCrossRef
116.
Mumm S, Jones J, Finnegan P, Whyte MP. Hypophosphatasia: molecular diagnosis of Rathbun’s original case. J Bone Min Res. 2001;16:1724–7.CrossRef
117.
Murshed M, Harmey D, Millan JL, McKee MD, Karsenty G. Unique coexpression in osteoblasts of broadly expressed genes accounts for the spatial restriction of ECM mineralization to bone. Genes Dev. 2005;19:1093–104.PubMedPubMedCentralCrossRef
118.
Russell RG, Bisaz S, Donath A, Morgan DB, Fleisch H. Inorganic pyrophosphate in plasma in normal persons and in patients with hypophosphatasia, osteogenesis imperfecta, and other disorders of bone. J Clin Invest. 1971;50:961–9.PubMedPubMedCentralCrossRef
119.
Kawai M, Kinoshita S, Kimoto A, Hasegawa Y, Miyagawa K, Yamazaki M, et al. FGF23 suppresses chondrocyte proliferation in the presence of soluble alpha-Klotho both in vitro and in vivo. J Biol Chem. 2013;288:2414–27.PubMedCrossRef
120.
Kinoshita S, Kawai M. The FGF23/KLOTHO Regulatory Network and Its Roles in Human Disorders. Vitam Horm. 2016;101:151–74.PubMedCrossRef
121.
Su CC, Kao CT, Hung CJ, Chen YJ, Huang TH, Shie MY. Regulation of physicochemical properties, osteogenesis activity, and fibroblast growth factor-2 release ability of beta-tricalcium phosphate for bone cement by calcium silicate. Mater Sci Eng C Mater Biol Appl. 2014;37:156–63.PubMedCrossRef
122.
123.
Liu J, Kwon TG, Nam HK, Hatch NE. Craniosynostosis-Associated Fgfr2(C342Y) Mutant Bone Marrow Stromal Cells Exhibit Cell Autonomous Abnormalities in Osteoblast Differentiation and Bone Formation. BioMed Res Int. 2013;2013:292506.PubMedPubMedCentral
124.
Hatch NE, Li Y, Franceschi RT. FGF2 stimulation of the pyrophosphate-generating enzyme, PC-1, in pre-osteoblast cells is mediated by RUNX2. J Bone Min Res. 2009;24:652–62.CrossRef
125.
Wang E, Nam HK, Liu J, Hatch NE. The Effects of Tissue-Nonspecific Alkaline Phosphatase Gene Therapy on Craniosynostosis and Craniofacial Morphology in the FGFR2(C342Y/+) Mouse Model of Crouzon Craniosynostosis. Orthod Craniofac Res. 2015;18(0 1):196–206.PubMedPubMedCentralCrossRef
126.
Ichikawa S, Austin AM, Gray AK, Econs MJ. A Phex mutation in a murine model of X-linked hypophosphatemia alters phosphate responsiveness of bone cells. J Bone Miner Res. 2012;27:453–60.PubMedCrossRef
127.
Ichikawa S, Gray AK, Bikorimana E, Econs MJ. Dosage effect of a Phex mutation in a murine model of X-linked hypophosphatemia. Calcif Tissue Int. 2013;93:155–62.PubMedPubMedCentralCrossRef
128.
Hana T, Tanaka S, Nakatomi H, Shojima M, Fukumoto S, Ikemura M, et al. Definitive surgical treatment of osteomalacia induced by skull base tumor and determination of the half-life of serum fibroblast growth factor 23. Endocr J. 2017;64(10):1033–9.PubMedCrossRef
129.
Yavropoulou MP, Gerothanasi N, Frydas A, Triantafyllou E, Poulios C, Hytiroglou P, et al. Tumor-induced osteomalacia due to a recurrent mesenchymal tumor overexpressing several growth factor receptors. Endocrinol Diabetes Metab Case Rep. 2015;2015:150025.PubMedPubMedCentral
130.
Aono Y, Yamazaki Y, Yasutake J, Kawata T, Hasegawa H, Urakawa I, et al. Therapeutic Effects of Anti-FGF23 Antibodies in Hypophosphatemic Rickets/Osteomalacia. J Bone Miner Res. 2009;24:1879–88.PubMedCrossRef
131.
Aono Y, Hasegawa H, Yamazaki Y, Shimada T, Fujita T, Yamashita T, et al. Anti-FGF-23 neutralizing antibodies ameliorate muscle weakness and decreased spontaneous movement of Hyp mice. J Bone Miner Res. 2011;26:803–10.PubMedCrossRef
132.
Wohrle S, Henninger C, Bonny O, Thuery A, Beluch N, Hynes NE, et al. Pharmacological inhibition of fibroblast growth factor (FGF) receptor signaling ameliorates FGF23-mediated hypophosphatemic rickets. J Bone Min Res. 2013;28:899–911.CrossRef
133.
134.
Insogna KL, Briot K, Imel EA, Kamenický P, Ruppe MD, Portale AA, et al. A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis. J Bone Miner Res. 2018;33:1383–93.PubMedCrossRef
135.
Carpenter TO, Whyte MP, Imel EA, Boot AM, Högler W, Linglart A, et al. Burosumab Therapy in Children with X-Linked Hypophosphatemia. N Engl J Med. 2018;378:1987–98.PubMedCrossRef
136.
Harrell RM, Lyles KW, Harrelson JM, Friedman NE, Drezner MK. Healing of bone disease in X-linked hypophosphatemic rickets/osteomalacia. Induction and maintenance with phosphorus and calcitriol. J Clin Invest. 1985;75:1858–68.PubMedPubMedCentralCrossRef
137.
Polisson RP, Martinez S, Khoury M, Harrell RM, Lyles KW, Friedman N, et al. Calcification of entheses associated with X-linked hypophosphatemic osteomalacia. N Engl J Med. 1985;313:1–6.PubMedCrossRef
138.
Skrinar A, Marshall A, Martin JS, Dvorak-Ewell M. X-Linked hypophosphatemia (XLH) impairs skeletal health outcomes and physical function in affected adults. Endocrine Reviews. 2015;36(2).
139.
Nehgme R, Fahey JT, Smith C, Carpenter TO. Cardiovascular abnormalities in patients with X-linked hypophosphatemia. J Clin Endocrinol Metab. 1997;82:2450–4.PubMedCrossRef
140.
141.
Patzer L, van’t Hoff W, Shah V, Hallson P, Kasidas GP, Samuell C, et al. Urinary supersaturation of calcium oxalate and phosphate in patients with X-linked hypophosphatemic rickets and in healthy schoolchildren. J Pediatr. 1999;135:611–7.PubMedCrossRef
142.
Alon U, Donaldson DL, Hellerstein S, Warady BA, Harris DJ. Metabolic and histologic investigation of the nature of nephrocalcinosis in children with hypophosphatemic rickets and in the Hyp mouse. J Pediatr. 1992;120:899–905.PubMedCrossRef
143.
Taylor A, Sherman NH, Norman ME. Nephrocalcinosis in X-linked hypophosphatemia: effect of treatment versus disease. Pediatr Nephrol. 1995;9:173–5.PubMedCrossRef
144.
145.
Sun GE, Suer O, Carpenter TO, Tan CD, Li-Ng M. Heart failure in hypophosphatemic rickets: complications from high-dose phosphate therapy. Endocr Pr. 2013;19:e8–11.CrossRef
146.
147.
Dinour D, Davidovits M, Ganon L, Ruminska J, Forster IC, Hernando N, et al. Loss of function of NaPiIIa causes nephrocalcinosis and possibly kidney insufficiency. Pediatr Nephrol. 2016;31:2289–97.PubMedCrossRef
148.
Rajagopal A, Braslavsky D, Lu JT, Kleppe S, Clement F, Cassinelli H, et al. Exome sequencing identifies a novel homozygous mutation in the phosphate transporter SLC34A1 in hypophosphatemia and nephrocalcinosis. J Clin Endocrinol Metab. 2014;99:E2451–6.PubMedPubMedCentralCrossRef
149.
Li Y, Caballero D, Ponsetto J, Chen A, Zhu C, Guo J, et al. Response of Npt2a knockout mice to dietary calcium and phosphorus. PLoS One. 2017;12:e0176232.PubMedPubMedCentralCrossRef
150.
Mitchell DM, Juppner H, Burnett-Bowie SM. FGF23 Is Not Associated With Age-Related Changes in Phosphate, but Enhances Renal Calcium Reabsorption in Girls. J Clin Endocrinol Metab. 2017;102:1151–60.PubMedPubMedCentralCrossRef
151.
Andrukhova O, Smorodchenko A, Egerbacher M, Streicher C, Zeitz U, Goetz R, et al. FGF23 promotes renal calcium reabsorption through the TRPV5 channel. EMBO J. 2014;33:229–46.PubMedPubMedCentral
152.
Andrukhova O, Slavic S, Smorodchenko A, Zeitz U, Shalhoub V, Lanske B, et al. FGF23 regulates renal sodium handling and blood pressure. EMBO Mol Med. 2014;6:744–59.PubMedPubMedCentralCrossRef
153.
Alon US, Monzavi R, Lilien M, Rasoulpour M, Geffner ME, Yadin O. Hypertension in hypophosphatemic rickets--role of secondary hyperparathyroidism. Pediatr Nephrol. 2003;18:155–8.PubMedCrossRef
154.
Vered I, Vered Z, Perez JE, Jaffe AS, Whyte MP. Normal left ventricular performance in children with X-linked hypophosphatemic rickets: a Doppler echocardiography study. J Bone Min Res. 1990;5:469–74.CrossRef
155.
156.
Panwar B, Jenny NS, Howard VJ, Wadley VG, Muntner P, Kissela BM, et al. Fibroblast growth factor 23 and risk of incident stroke in community-living adults. Stroke. 2015;46:322–8.PubMedPubMedCentralCrossRef
157.
Shah NH, Dong C, Elkind MS, Sacco RL, Mendez AJ, Hudson BI, et al. Fibroblast Growth Factor 23 Is Associated With Carotid Plaque Presence and Area: The Northern Manhattan Study. Arter Thromb Vasc Biol. 2015;35:2048–53.CrossRef
158.
Leifheit-Nestler M, Grosse Siemer R, Flasbart K, Richter B, Kirchhoff F, Ziegler WH, et al. Induction of cardiac FGF23/FGFR4 expression is associated with left ventricular hypertrophy in patients with chronic kidney disease. Nephrol Dial Transpl. 2016;31:1088–99.CrossRef
159.
Wright CB, Shah NH, Mendez AJ, DeRosa JT, Yoshita M, Elkind MS, et al. Fibroblast Growth Factor 23 Is Associated With Subclinical Cerebrovascular Damage: The Northern Manhattan Study. Stroke. 2016;47:923–8.PubMedPubMedCentralCrossRef
160.
Hao H, Li X, Li Q, Lin H, Chen Z, Xie J, et al. FGF23 promotes myocardial fibrosis in mice through activation of beta-catenin. Oncotarget. 2016;7:64649–64.PubMedPubMedCentralCrossRef
161.
Rotondi S, Pasquali M, Tartaglione L, Muci ML, Mandanici G, Leonangeli C, et al. Soluble α-Klotho Serum Levels in Chronic Kidney Disease. Int J Endocrinol. 2015;2015:872193.PubMedPubMedCentralCrossRef
162.
163.
Grabner A, Amaral AP, Schramm K, Singh S, Sloan A, Yanucil C, et al. Activation of Cardiac Fibroblast Growth Factor Receptor 4 Causes Left Ventricular Hypertrophy. Cell Metab. 2015;22:1020–32.PubMedPubMedCentralCrossRef
164.
Singh S, Grabner A, Yanucil C, Schramm K, Czaya B, Krick S, et al. Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease. Kidney Int. 2016;90:985–96.PubMedPubMedCentralCrossRef
165.
Andrukhova O, Slavic S, Zeitz U, Riesen SC, Heppelmann MS, Ambrisko TD, et al. Vitamin D is a regulator of endothelial nitric oxide synthase and arterial stiffness in mice. Mol Endocrinol. 2014;28:53–64.PubMedCrossRef
166.
Cianciolo G, Galassi A, Capelli I, Schillaci R, La Manna G, Cozzolino M. Klotho-FGF23, cardiovascular disease, and vascular calcification: black or white. Curr Vasc Pharmacol. 2018;16:143-56.
167.
Portale AA, Wolf MS, Messinger S, Perwad F, Juppner H, Warady BA, et al. Fibroblast Growth Factor 23 and Risk of CKD Progression in Children. Clin J Am Soc Nephrol. 2016;11:1989–98.PubMedPubMedCentralCrossRef
168.
Schnedl C, Fahrleitner-Pammer A, Pietschmann P, Amrein K. FGF23 in Acute and Chronic Illness. Markers. 2015;2015:358086.
169.
Liang G, Katz LD, Insogna KL, Carpenter TO, Macica CM. Survey of the Enthesopathy of X-Linked Hypophosphatemia and Its Characterization in Hyp Mice. Calcif Tissue Int. 2009;85:235–46.
170.
Che H, Roux C, Etcheto A, Rothenbuhler A, Kamenicky P, Linglart A, et al. Impaired quality of life in adults with X-linked hypophosphatemia and skeletal symptoms. Eur J Endocrinol. 2016;174:325–33.PubMedCrossRef
171.
Karaplis AC, Bai X, Falet JP, Macica CM. Mineralizing enthesopathy is a common feature of renal phosphate-wasting disorders attributed to FGF23 and is exacerbated by standard therapy in hyp mice. Endocrinology. 2012;153:5906–17.PubMedPubMedCentralCrossRef
172.
Saito T, Shimizu Y, Hori M, Taguchi M, Igarashi T, Fukumoto S, et al. A patient with hypophosphatemic rickets and ossification of posterior longitudinal ligament caused by a novel homozygous mutation in ENPP1 gene. Bone. 2011;49:913–6.PubMedCrossRef
173.
Makitie O, Pereira RC, Kaitila I, Turan S, Bastepe M, Laine T, et al. Long-term clinical outcome and carrier phenotype in autosomal recessive hypophosphatemia caused by a novel DMP1 mutation. J Bone Min Res. 2010;25:2165–74.CrossRef
174.
Liang G, Vanhouten J, Macica CM. An atypical degenerative osteoarthropathy in Hyp mice is characterized by a loss in the mineralized zone of articular cartilage. Calcif Tissue Int. 2011;89:151–62.PubMedCrossRef
175.
Hardy DC, Murphy WA, Siegel BA, Reid IR, Whyte MP. X-linked hypophosphatemia in adults: prevalence of skeletal radiographic and scintigraphic features. Radiology. 1989;171:403–14.PubMedCrossRef
176.
177.
D’Angelo M, Yan Z, Nooreyazdan M, Pacifici M, Sarment DS, Billings PC, et al. MMP-13 is induced during chondrocyte hypertrophy. J Cell Biochem. 2000;77:678–93.PubMedCrossRef
178.
Ruppe MD, Zhang X, Imel EA, Weber TJ, Klausner MA, Ito T, et al. Effect of four monthly doses of a human monoclonal anti-FGF23 antibody (KRN23) on quality of life in X-linked hypophosphatemia. Bone Rep. 2016;5:158–62.PubMedPubMedCentralCrossRef
179.
Veilleux LN, Cheung M, Ben Amor M, Rauch F. Abnormalities in muscle density and muscle function in hypophosphatemic rickets. J Clin Endocrinol Metab. 2012;97:E1492–8.PubMedCrossRef
180.
Veilleux LN, Cheung MS, Glorieux FH, Rauch F. The muscle-bone relationship in X-linked hypophosphatemic rickets. J Clin Endocrinol Metab. 2013;98:E990–5.PubMedCrossRef
181.
Bonewald LF. The Role of the Osteocyte in Bone and Nonbone Disease. Endocrinol Metab Clin North Am. 2017;46:1–18.PubMedCrossRef
182.
Schubert L, DeLuca HF. Hypophosphatemia is responsible for skeletal muscle weakness of vitamin D deficiency. Arch Biochem Biophys. 2010;500:157–61.PubMedCrossRef
183.
Chen Y-Y, Kao T-W, Chou C-W, Wu C-J, Yang H-F, Lai C-H, et al. Exploring the Link between Serum Phosphate Levels and Low Muscle Strength, Dynapenia, and Sarcopenia. Sci Rep. 2018;8:3573.PubMedPubMedCentralCrossRef
184.
Minisola S, Peacock M, Fukumoto S, Cipriani C, Pepe J, Tella SH, et al. Tumour-induced osteomalacia. Nat Rev Primer. 2017;3:17044.CrossRef
185.
Pesta DH, Tsirigotis DN, Befroy DE, Caballero D, Jurczak MJ, Rahimi Y, et al. Hypophosphatemia promotes lower rates of muscle ATP synthesis. Faseb J. 2016;30:3378–87.PubMedPubMedCentralCrossRef
186.
Larner AJ. Oral phosphate supplements reverse skeletal muscle abnormalities in a case of chronic fatigue with idiopathic renal hypophosphataemia. Neuromuscul Disord. 1994;4:155.PubMedCrossRef
187.
Hoshino C, Satoh N, Sugawara S, Kuriyama C, Kikuchi A, Ohta M. Sporadic adult-onset hypophosphatemic osteomalacia caused by excessive action of fibroblast growth factor 23. Intern Med. 2008;47:453–7.PubMedCrossRef
188.
Claus KN, Day TK, Wolf C. Neuromuscular signs associated with acute hypophosphatemia in a dog. J Am Anim Hosp Assoc. 2015;51:161–6.PubMedCrossRef
189.
Sato C, Iso Y, Mizukami T, Otabe K, Sasai M, Kurata M, et al. Fibroblast growth factor-23 induces cellular senescence in human mesenchymal stem cells from skeletal muscle. Biochem Biophys Res Commun. 2016;470:657–62.PubMedCrossRef
190.
Li DJ, Fu H, Zhao T, Ni M, Shen FM. Exercise-stimulated FGF23 promotes exercise performance via controlling the excess reactive oxygen species production and enhancing mitochondrial function in skeletal muscle. Metabolism. 2016;65:747–56.PubMedCrossRef
191.
Fukasawa H, Ishigaki S, Kinoshita-Katahashi N, Niwa H, Yasuda H, Kumagai H, et al. Plasma levels of fibroblast growth factor-23 are associated with muscle mass in haemodialysis patients. Nephrol Carlton. 2014;19:784–90.CrossRef
192.
Zoller H, Schaefer B, Glodny B. Iron-induced hypophosphatemia: an emerging complication. Curr Opin Nephrol Hypertens. 2017;26:266–75.PubMedCrossRef
193.
Caldemeyer KS, Boaz JC, Wappner RS, Moran CC, Smith RR, Quets JP. Chiari I malformation: association with hypophosphatemic rickets and MR imaging appearance. Radiology. 1995;195:733–8.PubMedCrossRef
194.
195.
Vega RA, Opalak C, Harshbarger RJ, Fearon JA, Ritter AM, Collins JJ, et al. Hypophosphatemic rickets and craniosynostosis: a multicenter case series. J Neurosurg Pediatr. 2016;17:694–700.PubMedCrossRef
196.
White KE, Cabral JM, Davis SI, Fishburn T, Evans WE, Ichikawa S, et al. Mutations that Cause Osteoglophonic Dysplasia Define Novel Roles for FGFR1 in Bone Elongation. Am J Hum Genet. 2005;76:361–7.PubMedCrossRef
197.
Di Rocco F, Biosse Duplan M, Heuze Y, Kaci N, Komla-Ebri D, Munnich A, et al. FGFR3 mutation causes abnormal membranous ossification in achondroplasia. Hum Mol Genet. 2014;23:2914–25.PubMedCrossRef
198.
Cohen MM Jr, Walker GF, Phillips C. A morphometric analysis of the craniofacial configuration in achondroplasia. J Craniofac Genet Dev Biol Suppl. 1985;1:139–65.PubMed
199.
Gjorup H, Kjaer I, Sonnesen L, Beck-Nielsen SS, Haubek D. Morphological characteristics of frontal sinus and nasal bone focusing on bone resorption and apposition in hypophosphatemic rickets. Orthod Craniofac Res. 2013;16:246–55.PubMed
200.
Iorio RJ, Murray G, Meyer RA Jr. Craniometric measurements of craniofacial malformations in mice with X-linked, dominant hypophosphatemia (vitamin D-resistant rickets). Teratology. 1980;22:291–8.PubMedCrossRef
201.
Katsianou MA, Adamopoulos C, Vastardis H, Basdra EK. Signaling mechanisms implicated in cranial sutures pathophysiology: Craniosynostosis. BBA Clin. 2016;6:165–76.PubMedPubMedCentralCrossRef
202.
Morriss-Kay GM, Wilkie AO. Growth of the normal skull vault and its alteration in craniosynostosis: insights from human genetics and experimental studies. J Anat. 2005;207:637–53.PubMedPubMedCentralCrossRef
203.
Murthy AS. X-linked hypophosphatemic rickets and craniosynostosis. J Craniofac Surg. 2009;20:439–42.PubMedCrossRef
204.
Carpenter TO, Imel EA, Ruppe MD, Weber TJ, Klausner MA, Wooddell MM, et al. Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia. J Clin Invest. 2014;124:1587–97.PubMedPubMedCentralCrossRef
205.
206.
Connor J, Olear EA, Insogna KL, Katz L, Baker S, Kaur R, et al. Conventional Therapy in Adults With X-Linked Hypophosphatemia: Effects on Enthesopathy and Dental Disease. J Clin Endocrinol Metab. 2015;100:3625–32.PubMedPubMedCentralCrossRef
207.
Baroncelli GI, Angiolini M, Ninni E, Galli V, Saggese R, Giuca MR. Prevalence and pathogenesis of dental and periodontal lesions in children with X-linked hypophosphatemic rickets. Eur J Paediatr Dent. 2006;7:61–6.PubMed
208.
Chaussain-Miller C, Sinding C, Septier D, Wolikow M, Goldberg M, Garabedian M. Dentin structure in familial hypophosphatemic rickets: benefits of vitamin D and phosphate treatment. Oral Dis. 2007;13:482–9.PubMedCrossRef
209.
Chen L, Liu H, Sun W, Bai X, Karaplis AC, Goltzman D, et al. Fibroblast growth factor 23 overexpression impacts negatively on dentin mineralization and dentinogenesis in mice. Clin Exp Pharmacol Physiol. 2011;38:395–402.PubMedCrossRef
210.
Fong H, Chu EY, Tompkins KA, Foster BL, Sitara D, Lanske B, et al. Aberrant cementum phenotype associated with the hypophosphatemic hyp mouse. J Periodontol. 2009;80:1348–54.PubMedPubMedCentralCrossRef
211.
Abe K, Masatomi Y, Nakajima Y, Shintani S, Moriwaki Y, Sobue S, et al. The occurrence of interglobular dentin in incisors of hypophosphatemic mice fed a high-calcium and high-phosphate diet. J Dent Res. 1992;71:478–83.PubMedCrossRef
212.
Ogawa T, Onishi T, Hayashibara T, Sakashita S, Okawa R, Ooshima T. Dentinal defects in Hyp mice not caused by hypophosphatemia alone. Arch Oral Biol. 2006;51:58–63.PubMedCrossRef
213.
Jones A, Tzenova J, Frappier D, Crumley M, Roslin N, Kos C, et al. Hereditary hypophosphatemic rickets with hypercalciuria is not caused by mutations in the Na/Pi cotransporter NPT2 gene. J Am Soc Nephrol. 2001;12:507–14.PubMedCrossRef
214.
Tenenhouse HS, Martel J, Gauthier C, Zhang MY, Portale AA. Renal expression of the sodium/phosphate cotransporter gene, Npt2, is not required for regulation of renal 1 alpha-hydroxylase by phosphate. Endocrinology. 2001;142:1124–9.PubMedCrossRef
215.
Chaussain-Miller C, Sinding C, Wolikow M, Lasfargues JJ, Godeau G, Garabedian M. Dental abnormalities in patients with familial hypophosphatemic vitamin D-resistant rickets: prevention by early treatment with 1-hydroxyvitamin D. J Pediatr. 2003;142:324–31.PubMedCrossRef
216.
Biosse Duplan M, Coyac BR, Bardet C, Zadikian C, Rothenbuhler A, Kamenicky P, et al. Phosphate and Vitamin D Prevent Periodontitis in X-Linked Hypophosphatemia. J Dent Res. 2017;96:388–95.PubMedCrossRef
217.
Cremonesi I, Nucci C, D’Alessandro G, Alkhamis N, Marchionni S, Piana G. X-linked hypophosphatemic rickets: enamel abnormalities and oral clinical findings. Scanning. 2014;36:456–61.PubMedCrossRef
218.
Carpenter TO, Gundberg CM. Osteocalcin abnormalities in Hyp mice reflect altered genetic expression and are not due to altered clearance, affinity for mineral, or ambient phosphorus levels. Endocrinology. 1996;137:5213–9.PubMedCrossRef
219.
Onishi T, Ogawa T, Hayashibara T, Hoshino T, Okawa R, Ooshima T. Hyper-expression of osteocalcin mRNA in odontoblasts of Hyp mice. J Dent Res. 2005;84:84–8.PubMedCrossRef
220.
Bronckers AL, Price PA, Schrijvers A, Bervoets TJ, Karsenty G. Studies of osteocalcin function in dentin formation in rodent teeth. Eur J Oral Sci. 1998;106:795–807.PubMedCrossRef
221.
222.
Nociti FH Jr, Berry JE, Foster BL, Gurley KA, Kingsley DM, Takata T, et al. Cementum: a phosphate-sensitive tissue. J Dent Res. 2002;81:817–21.PubMedCrossRef
223.
Beertsen W, VandenBos T, Everts V. Root development in mice lacking functional tissue non-specific alkaline phosphatase gene: inhibition of acellular cementum formation. J Dent Res. 1999;78:1221–9.PubMedCrossRef
224.
Nociti FH Jr, Foster BL, Tran AB, Dunn D, Presland RB, Wang L, et al. Vitamin D represses dentin matrix protein 1 in cementoblasts and osteocytes. J Dent Res. 2014;93:148–54.PubMedCrossRef
225.
Chu EY, Fong H, Blethen FA, Tompkins KA, Foster BL, Yeh KD, et al. Ablation of systemic phosphate-regulating gene fibroblast growth factor 23 (Fgf23) compromises the dentoalveolar complex. Anat Rec Hoboken. 2010;293:1214–26.PubMedPubMedCentralCrossRef
226.
Davies M, Kane R, Valentine J. Impaired hearing in X-linked hypophosphataemic (vitamin-D-resistant) osteomalacia. Ann Intern Med. 1984;100:230–2.PubMedCrossRef
227.
Fishman G, Miller-Hansen D, Jacobsen C, Singhal VK, Alon US. Hearing impairment in familial X-linked hypophosphatemic rickets. Eur J Pediatr. 2004;163:622–3.PubMed
228.
Pantel G, Probst R, Podvinec M, Gurtler N. Hearing loss and fluctuating hearing levels in X-linked hypophosphataemic osteomalacia. J Laryngol Otol. 2009;123:136–40.PubMedCrossRef
229.
Cherian KE, Kapoor N, Mathews SS, Paul TV. Endocrine Glands and Hearing: Auditory Manifestations of Various Endocrine and Metabolic Conditions. Indian J Endocrinol Metab. 2017;21:464–9.PubMedPubMedCentralCrossRef
230.
Wick CC, Lin SJ, Yu H, Megerian CA, Zheng QY. Treatment of ear and bone disease in the Phex mouse mutant with dietary supplementation. Am J Otolaryngol. 2017;38:44–51.PubMedCrossRef
231.
Meister M, Johnson A, Popelka GR, Kim GS, Whyte MP. Audiologic findings in young patients with hypophosphatemic bone disease. Ann Otol Rhinol Laryngol. 1986;95(4 Pt 1):415–20.PubMedCrossRef
232.
Boneh A, Reade TM, Scriver CR, Rishikof E. Audiometric evidence for two forms of X-linked hypophosphatemia in humans, apparent counterparts of Hyp and Gy mutations in mouse. Am J Med Genet. 1987;27:997–1003.PubMedCrossRef
233.
Megerian CA, Semaan MT, Aftab S, Kisley LB, Zheng QY, Pawlowski KS, et al. A mouse model with postnatal endolymphatic hydrops and hearing loss. Hear Res. 2008;237:90–105.PubMedPubMedCentralCrossRef
234.
Wang X, Levic S, Gratton MA, Doyle KJ, Yamoah EN, Pegg AE. Spermine synthase deficiency leads to deafness and a profound sensitivity to alpha-difluoromethylornithine. J Biol Chem. 2009;284:930–7.PubMedPubMedCentralCrossRef
235.
Wick CC, Semaan MT, Zheng QY, Megerian CA. A Genetic Murine Model of Endolymphatic Hydrops: The Phex Mouse. Curr Otorhinolaryngol Rep. 2014;2:144–51.PubMedPubMedCentralCrossRef
236.
O’Malley S, Ramsden RT, Latif A, Kane R, Davies M. Electrocochleographic changes in the hearing loss associated with X-linked hypophosphataemic osteomalacia. Acta Otolaryngol. 1985;100:13–8.PubMedCrossRef
237.
Melki SJ, Li Y, Semaan MT, Zheng QY, Megerian CA, Alagramam KN. A mouse model validates the utility of electrocochleography in verifying endolymphatic hydrops. J Assoc Res Otolaryngol. 2014;15:413–21.PubMedPubMedCentralCrossRef
238.
Momin SR, Melki SJ, Alagramam KN, Megerian CA. Spiral ganglion loss outpaces inner hair cell loss in endolymphatic hydrops. Laryngoscope. 2010;120:159–65.PubMedCrossRef
239.
Semaan MT, Zheng QY, Han F, Zheng Y, Yu H, Heaphy JC, et al. Characterization of neuronal cell death in the spiral ganglia of a mouse model of endolymphatic hydrops. Otol Neurotol. 2013;34:559–69.PubMedPubMedCentralCrossRef
240.
Semaan MT, Megerian CA. Contemporary perspectives on the pathophysiology of Meniere’s disease: implications for treatment. Curr Opin Otolaryngol Head Neck Surg. 2010;18:392–8.PubMedCrossRef
241.
Linthicum FH Jr, Doherty J, Webster P, Makarem A. The periductal channels of the endolymphatic duct, hydrodynamic implications. Otolaryngol Head Neck Surg. 2014;150:441–7.PubMedCrossRef
242.
Gurkov R, Speierer G, Wittwer L, Kalla R. Effect of Elevated Intracranial Pressure on Amplitudes and Frequency Tuning of Ocular Vestibular Evoked Myogenic Potentials Elicited by Bone-Conducted Vibration. Ear Hear. 2016;37:e409–13.PubMedCrossRef
243.
Kaya S, Tsuprun V, Hizli O, Schachern PA, Paparella MM, Cureoglu S. Cochlear changes in serous labyrinthitis associated with silent otitis media: A human temporal bone study. Am J Otolaryngol. 2016;37:83–8.PubMedCrossRef
244.
Melki SJ, Heddon CM, Frankel JK, Levitt AH, Momin SR, Alagramam KN, et al. Pharmacological protection of hearing loss in the mouse model of endolymphatic hydrops. Laryngoscope. 2010;120:1637–45.PubMedCrossRef
245.
Abdullah Z, Kurts C. More trouble with FGF23: a novel role in systemic immunosuppression. Kidney Int. 2016;89:1176–7.PubMedCrossRef
246.
Bacchetta J, Salusky IB, Hewison M. Beyond mineral metabolism, is there an interplay between FGF23 and vitamin D in innate immunity? Pediatr Nephrol. 2013;28:577–82.PubMedCrossRef
247.
Chonchol M, Greene T, Zhang Y, Hoofnagle AN, Cheung AK. Low Vitamin D and High Fibroblast Growth Factor 23 Serum Levels Associate with Infectious and Cardiac Deaths in the HEMO Study. J Am Soc Nephrol. 2016;27:227–37.PubMedCrossRef
248.
Ferreira C, Ziegler S, Gahl W. Generalized Arterial Calcification of Infancy. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, LJH B, Stephens K, et al., editors. GeneReviews((R)). Seattle (WA): University of Washington, Seattle; 1993.
249.
250.
251.
Areses-Trapote R, Lopez-Garcia JA, Ubetagoyena-Arrieta M, Eizaguirre A, Saez-Villaverde R. Hereditary hypophosphatemic rickets with hypercalciuria: case report. Nefrologia. 2012;32:529–34.PubMed
Metadata
Title
FGF23 and its role in X-linked hypophosphatemia-related morbidity
Authors
Signe Sparre Beck-Nielsen
Zulf Mughal
Dieter Haffner
Ola Nilsson
Elena Levtchenko
Gema Ariceta
Carmen de Lucas Collantes
Dirk Schnabel
Ravi Jandhyala
Outi Mäkitie
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Orphanet Journal of Rare Diseases / Issue 1/2019
Electronic ISSN: 1750-1172
DOI
https://doi.org/10.1186/s13023-019-1014-8

Other articles of this Issue 1/2019

Orphanet Journal of Rare Diseases 1/2019 Go to the issue

Research

Unsuccessful intravenous D-mannose treatment in PMM2-CDG

Research

Urea cycle disorders in Argentine patients: clinical presentation, biochemical and genetic findings

Research

Cardiac profile of the Czech population of Duchenne muscular dystrophy patients: a cardiovascular magnetic resonance study with T1 mapping

Research

Systemic bevacizumab for high-output cardiac failure in hereditary hemorrhagic telangiectasia: an international survey of HHT centers

Research

Evaluation of the frequency of non-motor symptoms of Parkinson’s disease in adult patients with Gaucher disease type 1

Research

Rare diseases in China: analysis of 2014–2015 hospitalization summary reports for 281 rare diseases from 96 tertiary hospitals